DEPTOR was shown to be an oncogene in hepatocellular carcinoma [71], ERα-negative breast cancer [72] and esophageal squamous cell carcinoma [73], multiple myeloma [70] and differentiated thyroid cancer [74], possibly through a"feedback model"mechanism. This evidence concerns the gene DEPTOR and plasma cell myeloma.